Subcutaneous Efgartigimod has been given FDA approval as a treatment for generalized myasthenia gravis.

Published Date: 22 Jun 2023

The phase 3 ADAPT-SC study, in which subcutaneous efgartigimod demonstrated a marginally better ability to reduce immunoglobulin than its previously approved intravenous formulation, served as the foundation for the FDA's decision.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Targeted radiation therapy shows near-complete response in rare sarcoma patients

2.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

3.

Germline Profiling May Improve Risk Stratification in t-MNs

4.

Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.

5.

Scientists call into question safety of potential new anticancer treatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot